上海君实生物医药科技股份有限公司 半年度评估报告 为进一步履行社会责任，全方位推动公司经营的持续优化与升级，上海君实 生物医药科技股份有限公司（以下简称"公司"）结合自身发展战略和经营情况， 制定了《上海君实生物医药科技股份有限公司 2025 年度"提质增效重回报"行 动方案》 （以下简称"2025 年行动方案"或"本方案"），详细情况参见公司已于 年上半年，公司切实履行并持续评估 2025 年行动方案的具体举措，现将 2025 年行动方案在 2025 年半年度（以下简称"报告期"）内的实施和效果评估情况报 告如下： 一、提升经营效率，加强合规建设，促进高质量发展 公司具备完整的从创新药物的发现和开发、在全球范围内的临床研究、大规 模生产到商业化的全产业链能力，旨在成为立足中国、布局全球的创新医药公司。 公司坚持质量为本、求真务实、诚信合规、追求卓越的企业价值观，致力于通过 源头创新以及合作开发等形式来研发 first-in-class（同类首创）或 best-in-class（同 类最优）的药物。公司的创新领域已从单抗药物类型持续扩展至包括小分子药物、 抗体偶联药物（ADC）、双特异性或多特异性抗体药物、融 ...

Group 1 - The core viewpoint is that the current wave of COVID-19 infections is manageable and does not warrant panic, particularly for the elderly with underlying health conditions [1] - The prediction indicates that the current wave is in a ramp-up phase and is expected to conclude by the end of June, lasting approximately 6 to 8 weeks [1] - The symptoms of the current COVID-19 wave are similar to previous ones, with notable symptoms including fever, headache, fatigue, and throat discomfort, with an increase in cough frequency [1] Group 2 - The circulating strain, XDV, is highly transmissible but has relatively lower pathogenicity compared to previous strains [2]

Core Viewpoint - The recent rise in COVID-19 positivity rates across multiple regions in China is concerning, but the situation is deemed manageable and not panic-inducing according to expert opinions [1][4][7]. Summary by Sections Current COVID-19 Trends - COVID-19 positivity rates in China have increased from 7.5% to 16.2% in outpatient flu-like cases and from 3.3% to 6.3% in hospitalized severe acute respiratory infections from March 31 to May 4 [5][6]. - The current wave of infections is expected to peak around the end of June, lasting approximately 6 to 8 weeks [4][7]. Demographics and Risks - The elderly population, particularly those aged 65 and above with underlying health conditions, are identified as high-risk groups [14][15]. - In Hong Kong, over 83% of reported COVID-19 deaths were among individuals aged 65 and older, with over 90% having comorbidities [3]. Symptoms and Variants - The circulating variant is identified as XDV, which exhibits strong transmissibility but relatively lower pathogenicity compared to previous strains [8][10]. - Common early symptoms include fever, headache, fatigue, and sore throat, with a notable increase in throat pain [9]. Treatment Recommendations - It is advised that high-risk individuals take antiviral medications such as Lopinavir, Nirmatrelvir, and Molnupiravir within 48 hours of symptom onset to prevent severe illness [15][20]. - Current antiviral medications are not recommended for children under 5 years due to a lack of clinical trial data [20]. Public Health Recommendations - Individuals are encouraged to wear masks in crowded places, maintain social distancing, ensure proper ventilation, and adopt healthy lifestyle habits to boost immunity [21][25][26].